On February 19, 2024, flags were flying in the factory areas of the company's subsidiaries Fushine Technology and Fushine Biology, waiting for the arrival of Changjiang District People's Congress representatives and CPPCC members to inspect Fushine Group's layout and planning in new industries in recent years, as well as the achievements and changes it has made.

On the afternoon of February 19th, nearly 400 deputies to the 4th Session of the 11th Changjiang District People's Congress and members of the 4th Session of the 9th Changjiang District Chinese People's Political Consultative Conference conducted a centralized inspection to gain firsthand insights into the progress of key projects in Changjiang District and to personally experience the significant achievements and encouraging changes in the district's economic and social development over the past year. The deputies and members of the Changjiang District People's Congress visited our subsidiaries, Fushine Technology and Fushine Biotechnology. Ni Weichun, Director of the Changjiang District High-Tech Zone Management Committee and Secretary of the Changjiang District Party Committee, Yi Wenbin, Deputy Secretary of the District Party Committee and District Mayor, and district leaders Jiang Zhifeng, Li Enqing, Cheng Bucai, Li Longjiang, Peng Xinjian, Zhou Wei, and Ning Yelin attended the inspection. Fushine Pharmaceuticals Deputy General Manager Dai Zhenliang (attending as a deputie to the People's Congress), Chen Yinghui, Assistant to the Chairman and Deputy General Manager of Fushine Group and General Manager of Fushine Technology, and Tu Yadong, General Manager of Fushine Biotechnology, were also in attendance.

During the inspection, representatives and committee members visited Fushine's microbial protein and new energy lithium battery electrolyte additive VC projects. Chen Yinghui, General Manager of Fushine Technology, detailed the company's layout and planning in the biopharmaceutical and new energy industries, and outlined the future development prospects of these industries, as well as the actual operating status of the projects. This gave the representatives and committee members a new understanding of Fushine's development. Chen Yinghui also explained that Fushine Group will continue to expand its investment in microbial protein and VC projects, leading the accelerated concentration of the biopharmaceutical industry and becoming a shining example of Jingdezhen Changjiang District's efforts to create a new engine for the development of the biopharmaceutical industry.

In recent years, relying on its accumulated experience in the pharmaceutical industry and its advantages in safety, environmental protection, production management, quality control, etc., combined with industry development trends and market demand, Fushine Group has been committed to expanding the research and development and industrialization of new medicines, new energy, synthetic biology and other fields, continuously improving the company's independent innovation capabilities and core competitiveness, and promoting the company's healthy, stable and sustainable development.